Andres J Yarur

List of Publications by Year
in descending order

56 papers	2,230 citations	257450 24 h-index	223800 46 g-index
61 all docs	61 docs citations	61 times ranked	2739 citing authors

#	Article	IF	Citations
1	Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 933-940.	3.7	226
2	Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events. American Journal of Gastroenterology, 2011, 106, 741-747.	0.4	205
3	The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut, 2016, 65, 249-255.	12.1	191
4	Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy. Clinical Gastroenterology and Hepatology, 2015, 13, 1118-1124.e3.	4.4	141
5	Prevalence of Thyroid Cancer in Multinodular Goiter Versus Single Nodule: A Systematic Review and Meta-Analysis. Thyroid, 2013, 23, 449-455.	4.5	122
6	The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Alimentary Pharmacology and Therapeutics, 2014, 39, 802-810.	3.7	121
7	Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with CrohnÊ¼s Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 409-415.	1.9	97
8	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014-2025.	0.4	93
9	Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Frontiers in Pharmacology, 2019, 10, 212.	3.5	92
10	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 486-493.	4.4	76
11	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1592-1601.e3.	4.4	69
12	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohnâ€™s Disease Based on Serum Levels of Proteins. Gastroenterology, 2020, 158, 515-526.e10.	1.3	65
13	Vedolizumab and Anti-Tumour Necrosis Factor Î± Real-World Outcomes in Biologic-NaÃ¯ve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. Journal of Crohn's and Colitis, 2021, 15, 1694-1706.	1.3	62
14	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	8.1	57
15	Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2015, 21, 1709-1718.	1.9	52
16	Therapeutic drug monitoring in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 3475.	3.3	51
17	Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 963-969.	1.3	42
18	Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2017, 23, 158-164.	1.9	41

#	Article	IF	Citations
19	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflammatory Bowel Diseases, 2018, 24, 849-860.	1.9	34
20	Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010â€“2019. Drug Safety, 2021, 44, 889-897.	3.2	34
21	Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2019, 64, 1651-1659.	2.3	32
22	Hepatobiliary Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1655-1667.	1.9	31
23	Predictors of aggressive inflammatory bowel disease. Gastroenterology and Hepatology, 2011, 7, 652-9.	0.1	31
24	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohn's & Colitis 360, 2022, 4, otac002.	1.1	28
25	Predictive factors for clinically actionable computed tomography findings in inflammatory bowel disease patients seen in the emergency department with acute gastrointestinal symptoms. Journal of Crohn's and Colitis, 2014, 8, 504-512.	1.3	27
26	Update on pregnancy and breastfeeding in the era of biologics. Digestive and Liver Disease, 2013, 45, 787-794.	0.9	21
27	Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology, 2018, 52, 537-544.	2.2	20
28	Real-World Effectiveness and Safety of Tofacitinib in Crohnâ€™s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clinical Gastroenterology and Hepatology, 2021, 19, 2207-2209.e3.	4.4	20
29	Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2020, 9, 3142.	2.4	17
30	Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases. Clinical Therapeutics, 2021, 43, 1392-1407.e1.	2.5	17
31	Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohnâ€™s Disease Patients. Journal of Gastrointestinal Surgery, 2015, 19, 1852-1861.	1.7	13
32	Realâ€world multicentre observational study including population pharmacokinetic modelling to evaluate the exposureâ€“response relationship of vedolizumab in inflammatory bowel disease: <scp>ERELATE</scp> Study. Alimentary Pharmacology and Therapeutics, 2022, 56, 463-476.	3.7	12
33	The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). Inflammatory Bowel Diseases, 2022, 28, 192-199.	1.9	11
34	The Impact of Hispanic Ethnicity and Race on Post-Surgical Complications in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2014, 59, 126-134.	2.3	10
35	Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Digestive Diseases and Sciences, 2018, 63, 1016-1024.	2.3	10
36	An approach to acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 943-955.	3.0	10

#	Article	IF	Citations
37	Cross-sectional analysis of patient phone calls to an inflammatory bowel disease clinic. Annals of Gastroenterology, 2015, 28, 357-365.	0.6	8
38	Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease. Advances in Therapy, 2022, 39, 738-753.	2.9	8
39	Inflammatory Cytokine Profile in Crohnâ€™s Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy. Journal of Clinical Gastroenterology, 2019, 53, 210-215.	2.2	7
40	Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. Journal of Crohn's and Colitis, 2020, 14, 1364-1377.	1.3	7
41	Therapeutic Drug Monitoring in Perianal Fistulizing Crohnâ€™s Disease. Journal of Clinical Medicine, 2022, 11, 1813.	2.4	4
42	Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflammatory Bowel Diseases, 2018, 24, 1291-1297.	1.9	3
43	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 3563-3569.	2.3	3
44	Vedolizumab Levels During Induction Are Associated With Remission in Patients With Inflammatory Bowel Diseases: 2017 Category Award (IBD): 2017 Presidential Poster Award. American Journal of Gastroenterology, 2017, 112, S353-S354.	0.4	2
45	Better Late than Never: Adding Thiopurines After Loss of Response to Infliximab Monotherapy. Digestive Diseases and Sciences, 2021, 66, 2851-2852.	2.3	1
46	Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring. Crohn's & Colitis 360, 2021, 3, .	1.1	1
47	The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases. Advances in Therapy, 2022, 39, 767-778.	2.9	1
48	Response to Raftery and O'Sullivan. American Journal of Gastroenterology, 2011, 106, 2042-2043.	0.4	0
49	Letter: is there a bi-directional relationship between depression and IBD? Authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 214-214.	3.7	0
50	Back to the Beginning: Restarting Infliximab in Inflammatory Bowel Disease Patients With Prior Loss of Response. Clinical Gastroenterology and Hepatology, 2014, 12, 1482-1484.	4.4	0
51	FERTILIDAD Y EMBARAZO EN PACIENTES CON ENFERMEDADES INFLAMATORIAS INTESTINALES. Revista MÃ©dica ClÃnica Las Condes, 2015, 26, 649-662.	0.2	0
52	Immune-mediated diseases and thromboembolic events: a modified Delphi panel. Current Medical Research and Opinion, 2021, 37, 1283-1291.	1.9	0
53	P087â€ƒPrevalence and Risk Factors for Developing Anastomotic Ring Inflammation After Ileal Resection and Ileo-Colonic Anastomosis in Patients With Crohnâ€™s Disease. American Journal of Gastroenterology, 2019, 114, S23-S23.	0.4	0
54	Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease. BMJ Open Gastroenterology, 2021, 8, e000788.	2.7	0

#	Article	IF	Citations
55	Intestinal Tissue Levels of Anti-Tumour Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases: Are We Looking in The Right Place at The Right Time?. Journal of Crohn's and Colitis, 2022, , .	1.3	0
56	Outcomes in patients with inflammatory bowel disease and acute gastrointestinal symptoms who test indeterminate for Clostridioides difficile. Annals of Gastroenterology, 2022, 35, 135-139.	0.6	0